<div id="readability-page-1"><p><span>AbbVie (NYSE:ABBV - Get Free Report)</span> was downgraded by research analysts at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report released on Sunday.</p><ul><li>The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat</li></ul><p>Several other brokerages have also commented on ABBV. DZ Bank upgraded AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, April 30th. William Blair  reiterated an &#34;outperform&#34; rating on shares of AbbVie in a report on Monday, March 9th. Bank of America upgraded AbbVie from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $234.00 price target on the stock in a report on Thursday, April 30th. The Goldman Sachs Group  restated a &#34;neutral&#34; rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Finally, Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of AbbVie in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned  a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $253.43.</p><p><b>Read Our Latest Analysis on AbbVie</b></p><h2>AbbVie Stock Performance</h2><ul><li>MarketBeat Week in Review – 04/27 - 05/01</li></ul><p>NYSE:ABBV opened at $210.54 on Friday. AbbVie has a fifty-two week low of $180.25 and a fifty-two week high of $244.81. The company has a market cap of $371.97 billion, a price-to-earnings ratio of 103.71, a PEG ratio of 0.73 and a beta of 0.32. The stock has a fifty day moving average price of $210.27 and a 200-day moving average price of $220.10. </p><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the company earned $2.46 EPS. AbbVie's revenue for the quarter was up 12.4% on a year-over-year basis.  Research analysts predict that  AbbVie will post 14.3 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><ul><li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li></ul><p>In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own  0.06% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several large investors have recently modified their holdings of ABBV. Chelsea Counsel Co. bought a new position in  AbbVie in the 3rd quarter valued at approximately $26,000.  Litman Gregory Wealth Management LLC purchased a new stake in  AbbVie during the 4th quarter valued at $28,000.  Westend Capital Management LLC purchased a new stake in shares of  AbbVie in the 4th quarter worth $29,000.  Imprint Wealth LLC increased its stake in shares of  AbbVie by 56.3% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares in the last quarter.  Finally, Texas Capital Bancshares Inc TX purchased a new stake in  AbbVie in the 3rd quarter worth $31,000. Hedge funds and other institutional investors own  70.23% of the company's stock. </p><h2>Trending Headlines about AbbVie</h2><p>Here are the key news stories impacting AbbVie this week:</p><ul>   <li><span>Positive Sentiment: </span>AbbVie’s Q1 results were supported by strong sales of <strong>Skyrizi</strong> and <strong>Rinvoq</strong>, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. <i></i><span>Article: How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?</span></li>   <li><span>Positive Sentiment: </span>Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably. <i></i><span>Article: AbbVie analyst estimate update</span></li>   <li><span>Positive Sentiment: </span>Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. <i></i><span>Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?</span></li> </ul><h2>AbbVie Company Profile</h2> (Get Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than AbbVie</li><li>3 Stocks to Own If Gas Prices Keep Rising</li><li>3 Crucial Aerospace Component Makers That Analysts Love</li><li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li><li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Wall Street Zen downgraded AbbVie (NYSE:ABBV) from a 'strong-buy' to a 'buy' rating. Other brokerages have varied opinions, with DZ Bank upgrading to 'strong-buy' and Bank of America setting a $234 price target. AbbVie reported Q1 earnings of $2.65 EPS, exceeding estimates, with revenue up 12.4% year-over-year. The stock has a consensus rating of 'Moderate Buy' and a price target of $253.43.</p>

AbbVie (NYSE:ABBV) Rating Lowered to Buy at Wall Street Zen